Crc January 2021

crc@lists.oulu.fi

15 participants
47 discussions

Reminder -> CALL OPEN: 4 Doctoral student positions in Health and Biosciences Doctoral Programme, deadline Jan 31
by Mirja Peltola 22 Jan '21

22 Jan '21

Kind Reminder Four Doctoral student positions in Health and Biosciences Doctoral Programme The North changes the world – more sustainable, more intelligent, more humane. We, at the University of Oulu, work as part of the international science community to produce new scientific information and science-based solutions. We are committed to educate future pioneers to build a more sustainable, intelligent and humane world. Creating new, taking responsibility and succeeding together are values that build a strong foundation for all our actions. We offer a working environment where individuals can cultivate their skills, do meaningful work, and develop professionally. Our university's several specialized research and service units enable extensive and diverse development and career opportunities for experts in various fields Four (4) Doctoral student positions in Health and Biosciences Doctoral Programme available for application Finnish UO website >>>><https://rekry.saima.fi/certiahome/open_job_view.html?did=5600&jc=1&id=00001…> English UO website >>>><https://rekry.saima.fi/certiahome/open_job_view.html?did=5600&jc=1&id=00001…> University of Oulu is now hiring highly motivated candidates for doctoral student positions in the doctoral programmes of the University of Oulu Graduate School (UniOGS). Successful candidates must commit to researcher training within Health and Biosciences Doctoral Programme with full-time work and to completing their degree within four years. DP-HBS gathers clinical medicine, biomedicine, biochemistry, molecular medicine, dentistry, health sciences, medical technology and biology under the umbrella of a multidisciplinary training programme. In the current call, there are four (4) full-time positions available in DP-HBS for 2021-2024. Eligibility and Requirements An eligible candidate has a Master’s degree or an equivalent degree in a field relevant to the applied field. The major subject of the doctoral student is expected to be in the Doctoral Degree Programme of Medicine, Biochemistry and Molecular Medicine, Health Sciences, Dentistry or Biology. The degree must have been completed before the selection with at least good grades. Applicants are expected to be at the very early stage of research, in practice starting their doctoral training with this position. If they already have doctoral study rights in University of Oulu or elsewhere, they need to explain why they should still be considered as starters and early-stage researchers. Any applicant who has received doctoral study rights 30.11.2019, or before, are ineligible to apply. Selected candidates must meet all the requirements to receive doctoral study rights as defined in: http://www.oulu.fi/uniogs/requirements_for_admission. In student selection, priority will be given to such doctoral students whose supervisor is not receiving strategic funding related to doctoral training from the University of Oulu during the applicable term, i.e. 2021 onwards. Prior to submitting, applicants are expected to find a prospective main supervisor in an eligible research unit. Applicants are advised to seek potential supervisors in the faculty web pages (https://www.oulu.fi/university/node/35079). The proposed main supervisor must clearly be identified in the application form (full name, title, position, faculty and research unit at the University of Oulu). A letter from the proposed supervisor willing to commit for supervision must be attached into the applicant’s set of documents (see below). Unless explicitly stated otherwise, the commitment letter does not bind the proposed supervisor to any commitment, if the applicant is not selected into the doctoral student position applied here and for which the letter of support was provided. Salary and key terms The salary of selected doctoral students will be initially set on level 2, and later on levels 2 – 4 of the national salary scale for the teaching and research staff of Finnish universities. In addition, a supplementary remuneration is given for personal achievement and performance (max. 50 %). In practice, the salary is roughly 2200 – 2700 € per month for an early stage researcher, depending on the appointee’s qualifications and progress of the doctoral thesis. Since this call is for starting doctoral researchers, the positions are filled at its earliest April 1, 2021 and ending December 31, 2024. A six-month trial period is applied in the positions. How to apply Submit your application through the online system by 31 January 2021. Please include the following attachments as five separate pdf files (please note that the online system has a maximum size limit for attachments): 1. CV: Including a list of all peer-reviewed scientific publications with full reference details. 2. Motivation letter: Describing prior knowledge, research interests and career plan (max 1 page). 3. Certificates/Diplomas: Scanned electronic copies of diplomas and transcripts of the records of relevant previous degrees. If the original documents are not in Finnish, Swedish or English, each document must be accompanied by an official certified translation into Finnish or English. 4. Research plan approved by the supervisor: Please follow the structure given in the guidelines of the Academy of Finland (https://www.aka.fi/en/research-funding/apply-for-funding/how-to-apply-for-f…) However, for the current purpose, the texts under the given section headings need not cover all bullet points in the guidelines, and the maximum length of the (draft) plan’s body of text must not exceed 3 pages with 10-12 point font size and with at least 1,5 cm margins. A fourth page can be used for the list of references only. Thus, the max total length of the plan including the references is 4 pages. Exceeding the page limit will either result in disqualification or removal of the extra pages from the document. 5. Letter of provisional commitment from the supervisor (https://www.oulu.fi/uniogs/node/208876 pre-formulated form that must be used): In this document the eligible supervisor (either a professor or a docent level researcher who is employed by the University of Oulu) states his/her willingness to act as the supervisor for the applicant. Commitment letter must include the provisional supervisor’s assurance that the research unit director is aware of and committed to the financial obligations related to these positions. The University will cover only part of the costs related to this position and the unit will cover the rest. Typically, 20-35% of the salary and sidecosts remain to be covered by research unit. All other other costs are to be covered by research unit. Applications received after the deadline, incomplete applications, and/or applications with attachments that exceed the specified limits, will not be considered. APPLY in SAIMA (Finnish text) >>>><https://rekry.saima.fi/certiahome/application_edit_welcome.html?field_id=0&…> APPLY in SAIMA (English text) >>>><https://rekry.saima.fi/certiahome/application_edit_welcome.html?field_id=0&…> Application and evaluation process Evaluation and ranking of the applications will take place in multiple stages. First, ineligible or incomplete applications are rejected. Second, eligible and complete applications are evaluated and ranked by the evaluation panel. Third, applications with highest scores from the second round will be further evaluated and ranked by the corresponding Doctoral Training Committee. Finally, University of Oulu Graduate School deans will consolidate the evaluation results and make the final decision for the positions. All applicants will be informed of the selection by e-mail. Further information About eligibility and degree requirements, see the Graduate School website: https://www.oulu.fi/uniogs/ About the evaluation process: DP-HBS coordinator Mirja Peltola (firstname.lastname(a)oulu.fi<mailto:firstname.lastname@oulu.fi>). Feel free to distribute this announcement further

1 0

Invitation/Kutsu: Health Tuesday Oulu - Cancer, from groundbreaking research to novel care
by Veera Virta 21 Jan '21

21 Jan '21

[cid:image003.png@01D6E9C5.C72F8E20] Welcome to Health Tuesday Oulu! When and where? Tuesday 2.2.2021. Business Finland's Health Tuesday webinar at 8:00, local Health Tuesday Oulu Teams meeting at 9:00-10:00. Next Health Tuesday provides insights into groundbreaking cancer research and novel care methods. In Business Finland's webinar you'll have the opportunity to learn about translating immuno-oncology into health actions, applying laser technology for cancer care, and uptaking of new research and technologies in cancer care. In the local meeting we'll have presentations from and discussion opportunities with the Northern Finland Regional Cancer Center FICAN North and Northern Finland Cancer Association (local program in Finnish). More information about the agenda and registration here<https://www.oulu.fi/cht/node/209008>. Registration by Monday, February 1st. Note! You're receiving this invitation as you have given consent to receiving event invitations and occasional other OuluHealth or CHT related news, or have registered lately to Health Tuesday events. If you don't want to have these messages in future, reply to veera.virta(a)oulu.fi<mailto:veera.virta@oulu.fi>. Do you want to receive information about CHT's, OuluHealth's and our other partners' events? Leave your contact information here<https://link.webropolsurveys.com/Participation/Public/b3b88e38-2ae4-4e85-95…>. _________________________________________________ Tervetuloa Health Tuesday Oulu -tilaisuuteen 2.2.2021 klo 8-10! Helmikuun Health Tuesday Oulu -tilaisuudessa kuullaan ajankohtaista tietoa syöpätutkimuksesta ja hoitomenetelmistä, niin Business Finlandin webinaarissa kuin Oulun paikallisessa Teams-tapaamisessa. Lisätietoja aamun agendasta ja ilmoittautumisohjeet täällä<https://www.oulu.fi/cht/node/209008>. Ilmoittauduthan viimeistään maanantaina 1.2. Tervetuloa mukaan! Huom! Saat tämän kutsun sähköpostiisi, koska olet ilmaissut meille halukkuutesi vastaanottaa tapahtumakutsuja ja satunnaisia muita uutisia OuluHealth:iin tai CHT:hen liittyen, tai olet ilmoittautunut Health Tuesday tapahtumiin kuluneen vuoden aikana. Mikäli et halua viestejä jatkossa, ilmoita tästä vastausviestinä veera.virta(a)oulu.fi<mailto:veera.virta@oulu.fi>. Do you want to receive information about CHT's, OuluHealth's and our other partners' events? Leave your contact information here<https://link.webropolsurveys.com/Participation/Public/b3b88e38-2ae4-4e85-95…>. Health Tuesday Oulu organized by: [cid:image002.png@01D6F00C.0C45E7B0] With kindest regards/Lämpimin terveisin, Veera Virta Coordinator Centre for Health and Technology P.O. Box 5000 FI-90014 Oulun yliopisto phone: +358503409870 email: veera.virta(a)oulu.fi<mailto:veera.virta@oulu.fi> [unnamed] www.oulu.fi/cht<http://www.oulu.fi/cht> www.facebook.com/chtoulu<https://www.facebook.com/chtoulu> ouluhealth.fi

1 0

FW: REMINDER: scanned images in NAS-space need to be transferred and erased asap
by Antti Haapalainen 21 Jan '21

21 Jan '21

From: Pia Nyberg <pia.nyberg(a)oulu.fi> Sent: 21. tammikuutata 2021 14:36 To: bco(a)lists.oulu.fi; fbmm <fbmm(a)lists.oulu.fi>; LTK-idm <LTK-idm(a)oulu.fi>; LTK <ltk-staff(a)oulu.fi>; bilsa(a)lists.oulu.fi; laakis(a)lists.oulu.fi; bioposti(a)lists.oulu.fi; genetics(a)lists.oulu.fi; biolaaket(a)lists.oulu.fi Subject: REMINDER: scanned images in NAS-space need to be transferred and erased asap Dear colleagues, The biobank slide scanner has been in constant use and now the university NAS-storage space is nearly full. Please go through your folders asap (and also proactively) in NAS and remove + transfer your images as soon as possible or at latest on Feb 5th. Let us know if this deadline causes insurmountable problems. After that all image files older than 2 month will be permanently removed by the Biobank staff. The researchers are strongly advised to see to that their images will be cleared from NAS promptly within 1 month of the scanning date. NAS has a limited space of 10 Tb (which fills up quite quickly) and thus it is not intended for long term storage of images. Please note that the university IT-services offers backed-up storage space (inquire them for current prices). BR Biobank Borealis Pia Nyberg Planning Manager, PhD, Adjunct Professor/Docent Northern Finland Biobank Borealis Oulu University Hospital Medical Research Center MRC PO Box 10, 90029 OYS Tel: +358-400-461 349 Email: pia.nyberg(a)ppshp.fi<mailto:pia.nyberg@ppshp.fi> or pia.nyberg(a)oulu.fi<mailto:pia.nyberg@oulu.fi> Learn more: https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-br… [biobankborealis_facelift-01]

1 0

FW: Kehityskeskustelukoulutus/Developmental discussion training
by Antti Haapalainen 21 Jan '21

21 Jan '21

From: Tiina Hurskainen <tiina.hurskainen(a)oulu.fi> Sent: 21. tammikuutata 2021 14:36 To: LTK-idm <LTK-idm(a)oulu.fi>; fbmm <fbmm(a)lists.oulu.fi>; bco-staff(a)lists.oulu.fi; LTK <ltk-staff(a)oulu.fi> Subject: Kehityskeskustelukoulutus/Developmental discussion training Yliopisto järjestää koko henkilöstölle kehityskeskustelukoulutusta zoomissa 15.2.2021 - klo 12-13 (suomeksi) - klo 13-14 /englanniksi) Seuraa patiosta tarkempia ohjeita! The UO is arranging developmental discussion training in zoom to all personnel in Feb 15th 2021 - at 12-13 (FIN) - at 13-14 (ENG) Please, follow patio for further information! Tiina Hurskainen Henkilöstöpäällikkö | HR Manager Oulun yliopisto | University of Oulu Henkilöstöpalvelut | HR Services Tel. +358 40 7040270 PO Box 5000, FI-90014 OULUN YLIOPISTO www.oulu.fi<http://www.oulu.fi/yliopisto> [cid:image001.jpg@01D6F002.585589D0]

1 0

Horizon Europe Health cluster brokerage event
by Emma Pirilä 21 Jan '21

21 Jan '21

Dear researchers, there is going to be a Health technology brokerage event for those interested in finding partners for the upcoming Horizon Europe Health cluster calls. The event is fully virtual so please just go ahead and sign up! :) For more information and registration information: https://www.hth-styria.com/ With best regards, Emma ************************ Emma Pirilä, PhD Research Funding Specialist Faculty of Medicine Faculty of Biochemistry and Molecular Medicine Biocenter Oulu Aapistie 5A, 2nd floor FIN- 90230 University of Oulu Finland Phone: +358503426428 e-mail: emma.pirila(a)oulu.fi<mailto:emma.pirila@oulu.fi> ************************

1 0

Päivityksiä henkilöstön koronaohjeisiin / Updates in Covid-19 guidelines for staff
by Antti Haapalainen 21 Jan '21

21 Jan '21

Hei, Tässä muutama tärkeä päivitys henkilöstön koronaohjeisiin. Kaikissa kohtaamisissa tulee huomioida 2 metrin turvaväli. Oulun yliopisto suosittelee käyttämään suu-nenäsuojainta yliopiston tiloissa aina, kun se on mahdollista. THL suosittelee kasvomaskin käyttöä aina, jos samassa tilassa työskentelee tai oleskelee useampia henkilöitä. Suojainta ei tarvitse kuitenkaan käyttää esimerkiksi silloin, kun henkilö työskentelee yksin esimerkiksi omassa työhuoneessaan. Lisäinfoa löytyy: https://patio.oulu.fi/fi/yliopisto/ajankohtaiset-teemat/koronavirus Hi, Here are a few updates in Covid-19 guidelines for staff. Safe distance of 2 metres must be kept. The University of Oulu recommends to use face mask on campuses in all situations where it is possible. Finnish institute for health and welfare recommends wearing a mask always if several people work and stay in the same facility. The recommendation applies to all facilities at our university, but not to situations when a person is working alone e.g. in the own office. More information can be found: https://patio.oulu.fi/en/university/topical-themes/coronavirus Terv. Antti

1 0

EMA two-part CTIS training event targeted at SME and academia
by Emma Pirilä 21 Jan '21

21 Jan '21

Dear researchers, please find information on Clinical Trial Information System - training by the European Medicines Agency. Registration is necessary to participate in the two-day training. This is very relevant and timely for everyone involved and interested in clinical trials. Best regards, Emma Please find and forward this announcement on a two-part CTIS training event targeted at SME and academia clinical trial sponsors (future CTIS users and their organisations). Day 1: 22 Feb 2021 SME and academia Clinical Trials Information System (CTIS) two-part training webinar: Day 1 | European Medicines Agency (europa.eu)<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> Day 2: 4 Mar 2021 SME and academia Clinical Trials Information System (CTIS) two-part training webinar: Day 2 | European Medicines Agency (europa.eu)<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> The way clinical trials are conducted in the EU will undergo a major change when the Clinical Trial Regulation (Regulation (EU) No 536/2014) comes into application. The Regulation harmonises the assessment and supervision processes for clinical trials throughout the EU, via a Clinical Trials Information System (CTIS). CTIS will contain the centralised EU portal and database for clinical trials foreseen by the Regulation and will be used by clinical trial sponsors as a single entry point in the EU to obtain approval for clinical trials based on applications and for monitoring clinical trials during their life cycle, including the submission of summary of results. The system is currently under development and will have collaboration and communication tools, workflow and document management capabilities. It will include a user management tool to enable access for sponsors, Member States and the European Commission via dedicated workspaces. It will also provide general public with access to clinical trials information. CTIS will centralise the submission process for clinical trial applications and the assessment and authorisation by Member States in a single unique platform. It will facilitate day-to-day business processes of Member States and sponsors of clinical trials throughout the lifecycle of a clinical trial harmonising submission and maintenance of trial applications, assessment and supervision of trials and promoting patient safety and transparency. The Clinical Trials Regulation, Regulation (EU) No 536/2014, will become applicable as CTIS goes live, which is anticipated in December 2021. Once launched, CTIS will be immediately available for authorities and for clinical trial sponsors, while a three-year phased transition period from the current Directive 2001/20/EC to the Regulation will apply. To facilitate preparedness for use of CTIS users, the European Medicines Agency has developed a training programme to provide future CTIS users with the skills and knowledge to successfully use CTIS into their business. A wide array of comprehensive online training material will be made available gradually in 2021. For Micro, Small to Medium Enterprises (SMEs) and academia, EMA is organising a targeted webinar to provide training on CTIS and its functionalities. The webinar is divided into two parts (Day 1 and Day 2) and participants are advised to attend both. This two-part event is free of charge. As per current planning, Day 1 on 22nd February 2021 will present CTIS access management, user management and different roles in CTIS. Day 2 on 4th March 2021 will focus on CTIS functionalities - how to submit and manage a clinical trial application. Transparency of reporting of results will also be presented on Day 2. The webinar will include presentations by speakers from EMA system experts and presenters from SME and academic institutions, demonstration of the system, and opportunities for questions and answers. The webinar will be recorded and published for future perusal. Steps to take: 1) Express your initial interest in this two-part CTIS training event aimed at SMEs and academia by completing the expression of interest questions: EUSurvey - Survey (europa.eu)<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fec.europa…>. This initial expression of interest should be made by the 29th January 2021 but is not yet the registration to the training. 2) Based on expressions of interest, you will receive a separate email from EMA including a link to register for the training in the week commencing on 1st February 2021. Registrations will close on 7th February 2021. You will need to register for both dates individually. Due to the platform used, this two-part CTIS training event is limited to 950 participants. Should more participants express interest to participate, preference will be given to those representing academic institutions and SMEs. The criteria for being classified as an SME can be found here<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…>. For more information on - this SME/academia event, please contact CT.Sponsortraining(a)ema.europa.eu<mailto:CT.Sponsortraining@ema.europa.eu>. Replies to this email are directed to CT.Sponsortraining(a)ema.europa.eu<mailto:CT.Sponsortraining@ema.europa.eu> - EMA support for SMEs, please see https://www.ema.europa.eu/en/human-regulatory/overview/supporting-smes<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> - EMA engagement with academia, please see https://www.ema.europa.eu/en/partners-networks/academia<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> To stay up to date with developments and plans, please see our CTIS Highlights NewsLetters: https://www.ema.europa.eu/en/news-events/publications/newsletters#clinical-…<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> (to subscribe write to CT.communication(a)ema.europa.eu<mailto:CT.communication@ema.europa.eu>). With kind regards from the CTIS Change management team Fia Westerholm Programme Assurance Manager Clinical Trials Information System (CTIS) programme Clinical Trials and Manufacturing Task Force European Medicines Agency Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands Telephone +31 (0)88 781 8581 Fia.Westerholm(a)ema.europa.eu<mailto:Fia.Westerholm@ema.europa.eu> | www.ema.europa.eu<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> | For directions, see How to find us<https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> Follow us: [Twitter-icon] <https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Ftwitter.c…> [RSS-icon] <https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ema.e…> [Youtube-icon] <https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.youtu…> This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately. Classified as confidential by the European Medicines Agency ########################################### This message has been scanned by Trend Micro IMSS antivirus.

1 0

Kontinkangas Campus Science Day 2021; abstract submission open till January 22
by Anne Vainionpää 21 Jan '21

21 Jan '21

Dear All, Kontinkangas Campus Science Day will be arranged on Tuesday, February 23, 2021. Theme of the day is "Viruses affecting health and research". The event will be arranged virtually. Science Day pages will be found here: https://www.oulu.fi/sciencedaykontinkangas/ Abstract submission is open till tomorrow, Friday, January 22. Here is the link to the abstract submission: https://www.oulu.fi/sciencedaykontinkangas/registration-opened Best wishes, Anne ********************** Anne Vainionpää Management assistant Faculty of Medicine

1 0

FW: Lippincott-sopimukseen sisältyy maksuttomia OA-artikkeleita vuonna 2021
by Katja Riipinen 20 Jan '21

20 Jan '21

Tiedoksi Lähettäjä: Mari Katvala <mari.katvala(a)oulu.fi<mailto:mari.katvala@oulu.fi>> Lähetetty: tiistai 19. tammikuuta 2021 10.31 Aihe: Lippincott-sopimukseen sisältyy maksuttomia OA-artikkeleita vuonna 2021 FinELibin Lippincott Total Acces minus Neurology-lehtipakettisopimukseen sisältyy mahdollisuus julkaista rajoitettu määrä artikkeleita avoimena maksutta CCBY-tai CCBY-NC-ND-lisensseillä sopimuskauden aikana. Oulun yliopiston (ml. yliopistosairaala) tutkijoilla on oikeus julkaista 12 maksutonta OA-artikkelia v. 2021. Kirjoittajan tulee käsikirjoitusta jättäessään syöttää Wolters Kluwerin maksujärjestelmään (http://wolterskluwer.qconnect.com) organisaatiokohtainen koodi, jonka perusteella kustantaja tunnistaa kirjoittajan oikeuden maksuttomaan OA-artikkeliin. KOODIN SAA PYYTÄMÄLLÄ osoitteesta openpublishing(a)oulu.fi<mailto:openpublishing@oulu.fi> Organisaatiokohtaista koodia käyttäessään kirjoittaja saa julkaista artikkelinsa avoimena ilman APC-maksua. Vuoden 2021 koodia voi käyttää artikkeliin, joka hyväksytään julkaistavaksi vuoden 2021 aikana. Ohjeet kirjoittajille FinELibin verkkosivuilla -suomeksi: http://finelib.fi/oa-julkaiseminen-wolters-kluwer-lippincott-lehdissa/ -englanniksi: http://finelib.fi/open-access-publishing-in-wolters-kluwer-lippincott-journ… Wolters Kluwer on myös julkaissut vastaavat ohjeet kirjoittajille: http://tools.ovid.com/openaccess/finelib/ Oulun yliopiston kirjasto - Julkaisupalvelut / Oulu University Library - Publishing Services ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Mari Katvala Informaatikko / Senior Information Specialist Oulun yliopiston kirjasto<http://www.oulu.fi/kirjasto/> / Oulu University Library<http://www.oulu.fi/library/node/40442> PL 7500 / PO. Box 7500 90014 Oulun yliopisto / FI-90014 University of Oulu Finland puh./ tel. 48 3558, +358 29 4483 558

1 0

Webinar: Who owns IPR? - 25.1. / 2.2.
by Maarit Jokela 19 Jan '21

19 Jan '21

Researcher / teacher, IPR (intellectual property rights) issues are often raised in research projects. Business partners ask what benefits they will get from participating in the project. At what cost can the results be accessed? Come to the webinar! Maarit Jokela, Innovation Manager of University Innovation Centre will tell: 25.1. at 3-4 pm in Finnish (Participation link: https://oulu.zoom.us/j/63871206601 <https://oulu.zoom.us/j/67758714502> ) 2.2. at 3-4 pm in English (Participation link: https://oulu.zoom.us/j/63871206601 <https://oulu.zoom.us/j/67758714502> ) * Who owns the IPRs generated in the study? Researcher, university or company involved in the project? * What can be promised to companies when asked to participate in research projects? * How are IPR matters agreed? How are they compensated? Welcome! No pre-registration. Best wishes, Maarit Maarit Jokela, PhD (Biochem.) Innovation Manager University of Oulu University Innovation Centre P.O.Box 4300 (street address: Erkki Koiso-Kanttilan katu 1) FI-90014 University of Oulu FINLAND tel. +358-40-355 9660 Internal mail: 8 INNO Room: YT105 / Linnanmaa campus https://fi.linkedin.com/in/maaritjokela [cid:image003.jpg@01D6EE62.5F328380] Follow us on Facebook<https://www.facebook.com/unioulu/>, Instagram<https://www.instagram.com/unioulu/?hl=fi>, Linkedin<https://www.linkedin.com/school/university-of-oulu/> and Twitter<https://twitter.com/unioulu>. The content of this message is confidential. If you are not a recipient indicated or intended in this message or you think this message may have been addressed to you in error, please inform us by an email reply and then delete the message. In such case it is forbidden to copy, forward, or in any way reveal the contents of this message to anyone

1 0

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

Crc January 2021